Tc 99m ethylenedicysteine deoxyglucose

Drug Profile

Tc 99m ethylenedicysteine deoxyglucose

Alternative Names: (99m)Tc ethylenedicysteine-deoxyglucose; 99m-Tc-EC-DG; 99mTC ethylene dicysteine deoxyglucose; 99mTc ethylenedicysteine N-acetyl glucosamine; 99mTc-oncardia; Oncardia; Tc 99m EC glucosamine; Tc 99m ethylenedicysteine glucosamine; Technetium TC 99m ECDG; Technetium-99m-labeled Ethylenedicysteine-Deoxyglucose; Technetium-99m-labeled ethylenedicysteine-glucosamine

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CellPoint LLC
  • Developer CellPoint; University of Chicago
  • Class Diagnostic conjugates; Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Lung cancer; Myocardial ischaemia

Highest Development Phases

  • Phase III Lung cancer
  • Phase II Myocardial ischaemia
  • No development reported Head and neck cancer; Non-small cell lung cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Diagnosis) in USA (IV, Injection)
  • 03 Aug 2015 No recent reports on development identified - Phase-II for Non-small cell lung cancer (Diagnosis) in Canada (IV)
  • 01 Feb 2015 Tc 99m ethylenedicysteine deoxyglucose is still in phase II trials for Myocardial ischaemia (Diagnosis) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top